Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
A Vyas, R Gomez-Casal… - Proceedings of the …, 2022 - National Acad Sciences
Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy.
A Vyas, R Gomez-Casal, S Cruz-Rangel… - Proceedings of the …, 2022 - europepmc.org
Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
A Vyas, R Gomez-Casal… - Proceedings of the …, 2022 - pubmed.ncbi.nlm.nih.gov
Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
A Vyas, R Gomez-Casal… - Proceedings of the …, 2022 - ui.adsabs.harvard.edu
Cisplatin is the first line therapy for patients with head and neck cancer. However, resistance
to cisplatin remains a major concern. High expression of the calcium-activated chloride …
to cisplatin remains a major concern. High expression of the calcium-activated chloride …
[HTML][HTML] Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
A Vyas, R Gomez-Casal, S Cruz-Rangel… - Proceedings of the …, 2022 - ncbi.nlm.nih.gov
Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
A Vyas, R Gomez-Casal… - … of the National …, 2022 - mdanderson.elsevierpure.com
Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …
continues to have low cure rates despite the recent advances in therapies. Cisplatin is the …